As of March 2026, the European Union has shifted to a proactive era of Strategic Autonomy, guided by the 2024–2029 Strategic Agenda. Focused on sovereignty, security, and sustainability, the EU strengthens economic competitiveness, advances defense capabilities, and links governance funding to democratic performance.

In trade, Latin America emerges as a key strategic partner. The EU-Mercosur deal, Modernized Mexico Agreement, and Global Gateway projects support sustainable investment, digital infrastructure, and resilient supply chains.

Public health policy in 2026 emphasizes cross-border solidarity, particularly for rare diseases. The European Blueprint for Rare Diseases, launched at the 2026 European Conference on Rare Diseases, integrates genomics, digital health data, and strategic precision medicine. The European Health Data Space enables specialists across member states to access anonymized patient data, accelerating diagnosis and treatment.

EURORDIS’ key advocacy priorities guide this effort:

1. A European ecosystem for rare diseases: A goal-based EU Action Plan to address unmet needs and unify legislative initiatives.
2. Faster, accurate diagnoses: Integrated approaches, EU-wide screening, and shared best practices for equitable care.
3. Integrated healthcare pathways: European Reference Networks ensure timely, equal access to specialized care.
4. Access to innovative treatments: Systematic patient engagement, coordinated pricing, and reimbursement.
5. Person-centered, lifelong care: Support for holistic care, mental health, and improved disability assessments.
6. Needs-led research and development: Cross-border collaboration and Horizon Europe partnerships.
7. Optimized health data use: Harmonized, interoperable data systems with ethical patient-centric governance.
8. Sustainable treatment development: Digital tools, environmental responsibility, and industry collaboration.

These priorities build on two decades of EU-level progress, from the Orphan Medicinal Products Regulation to the European Reference Networks. The Rare2030 Foresight Study outlines a roadmap for the next decade, reinforcing rare diseases as a public health priority across Europe.

Europe’s policy philosophy—Sustainable by Design, Innovative by Digital—now encompasses both strategic global positioning and leadership in health, ensuring coordinated action benefits citizens, patients, and partner regions alike.